Kognezil (Donepezil Hydrochloride)

Donepezil reversibly inhibits the enzyme acetylcholinesterase, which normally breaks down the neurotransmitter acetylcholine. By blocking this enzyme, donepezil raises acetylcholine levels in the central nervous system, supporting nerve signal transmission that is important for memory and learning.

The dosage of Kognezil is individualized by the prescribing clinician based on the patient’s condition, response, and tolerability. The prescriber determines the appropriate strength and titration schedule, and patients should follow the specific instructions provided by their healthcare professional.

The safety of donepezil during pregnancy and lactation has not been established. It is classified as pregnancy category unknown, and clinicians usually avoid prescribing it to pregnant or nursing women unless the potential benefit justifies the potential risk.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Kognezil (donepezil) belongs to the acetylcholinesterase inhibitor class, similar to rivastigmine and galantamine. Compared with these agents, donepezil is often preferred for its once‑daily dosing and a broader evidence base for mild to moderate disease, though individual response and tolerability vary.

Kognezil tablets should be stored at ambient temperature below 25 °C, in the original container, protected from moisture and direct sunlight. Do not store in humid environments such as bathrooms, and keep out of reach of children.

Kognezil is taken orally, usually once daily with or without food. The tablet should be swallowed whole with a glass of water. Patients should follow the dosing schedule prescribed by their healthcare provider and not alter the regimen without medical advice.

Serious risks include significant bradycardia, cardiac conduction abnormalities, severe vomiting leading to dehydration, seizures, and rare cases of liver injury or severe allergic reactions. Patients should report any fainting, rapid heartbeat changes, persistent vomiting, or rash to their physician promptly.

Kognezil should be avoided in individuals with known hypersensitivity to donepezil or any acetylcholinesterase inhibitor, patients with severe cardiac conduction disorders, uncontrolled asthma or COPD, and those taking strong anticholinergic medications that would counteract its effect.